disitamab vedotin: Clinical Trials

78 trials of disitamab vedotin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 recruiting, 18 not yet recruiting, 18 unknown, 7 active not recruiting. 60 Phase 2, 12 Phase 3, 9 Phase 1, 3 Not applicable, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 260Recruiting 23, Not yet recruiting 16, Unknown 14, Active not recruiting 6, Withdrawn 1
Phase 312Recruiting 7, Not yet recruiting 3, Active not recruiting 2
Phase 19Recruiting 5, Not yet recruiting 2, Active not recruiting 1, Unknown 1
Not applicable3Recruiting 2, Not yet recruiting 1
Phase 42Unknown 2
Early Phase 11Recruiting 1

Follow disitamab vedotin: new trials by email Literature Review of disitamab vedotin trials Research Report on disitamab vedotin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer
Phase 1Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University202027-01-012026-11-05
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates
Phase 2Not yet recruitingTianjin Medical University Second Hospital1502026-10-202026-10-23
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Phase 2 / Phase 3Not yet recruitingTianjin Medical University Second Hospital1142026-08-012026-08-10
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
Sintilimab, disitamab vedotin - Sebaceous Gland Carcinoma
Phase 2Not yet recruitingWest China Hospital252026-08-012026-08-03
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC
Phase 3RecruitingZhiquan Hu1702026-07-012026-07-09
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University802026-07-012026-07-21
HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC
Disitamab Vedotin (RC48), Gemcitabine + Cisplatin(GC)+Toripalimab, Toripalimab (JS001 ) - Urinary Bladder Neoplasms
Phase 2 / Phase 3Not yet recruitingWest China Hospital2402026-06-202026-05-27
Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial
Disitamab vedotin + Sintilimab + Multimodality radiotherapy - HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruitingWest China Hospital302026-06-012026-08-03
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC
Drug: Disitamab Vedotin - Upper Urinary Tract Urothelial Carcinoma
Phase 2Not yet recruitingRenJi Hospital492026-05-162026-05-18
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2) - Upper Tract Urothelial Carcinoma
Phase 3RecruitingPeking University First Hospital1922026-05-012026-09-28
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
disitamab vedotin, sintilimab, capecitabine - Rectal Cancer
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology292026-04-222026-04-03
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
Tunlametinib+PD-1 mAb - Gastric Adenocarcinoma
Phase 2Not yet recruitingSun Yat-sen University762026-04-012026-04-02
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC)
Phase 2Not yet recruitingchenxu1462026-03-262026-03-17
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Disitamab Vedotin, Gemcitabine, Capecitabine - HER2-positive Breast Cancer, Metastatic Breast Cancer
Phase 2 / Phase 3Not yet recruitingFudan University2682026-01-162026-01-26
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine) - Gastric Carcinoma
Phase 3RecruitingRemeGen Co., Ltd.5552026-01-122026-09-22
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
Disitamab Vedotin, PD-1 inhibitor, radiotherapy - Bladder (Urothelial, Transitional Cell) Cancer
Phase 2Not yet recruitingRenJi Hospital452025-09-012025-08-26
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Disitamab Vedotin, Lenvatinib, Pembrolizumab - Biliary Tract Cancer, Disitamab Vedotin
Phase 2Not yet recruitingPeking Union Medical College Hospital652025-08-302025-09-08
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II Study
Disitamab Vedotin (RC48), Abiraterone + prednisone - mCRPC
Phase 2RecruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School202025-07-202025-07-30
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Disitamab vedotin - Breast Cancer, Breast Neoplasms
Phase 1 / Phase 2Active not recruitingPfizer742025-06-302026-11-05
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Disitamab Vedotin Injection, Ivonescimab(AK112,a PD-1/VEGF bispecific antibody), Radical Cystectomy with Pelvic Lymph Node Dissection - Bladder Cancer, Muscle-invasive Bladder Cancer
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University302025-04-302025-05-04

Showing 20 of 78. Sign in to see all of them.

Conditions studied

Breast Neoplasms (13)  ·  Stomach Neoplasms (10)  ·  Urinary Bladder Neoplasms (9)  ·  Carcinoma, Transitional Cell (6)  ·  Colorectal Neoplasms (3)  ·  Non-Muscle Invasive Bladder Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Adenocarcinoma, Sebaceous (1)  ·  Biliary Tract Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Head and Neck Neoplasms (1)

Sponsors

RemeGen Co., Ltd. (13)  ·  RenJi Hospital (6)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6)  ·  Sun Yat-sen University (5)  ·  Seagen, a wholly owned subsidiary of Pfizer (4)  ·  The First Affiliated Hospital with Nanjing Medical University (4)  ·  Tianjin Medical University Second Hospital (4)  ·  West China Hospital (4)  ·  Fudan University (3)  ·  Qilu Hospital of Shandong University (3)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  Peking University First Hospital (2)  ·  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2)

Countries

China (62)  ·  Australia (5)  ·  Canada (5)  ·  Italy (5)  ·  Spain (5)  ·  United States (5)  ·  Japan (4)  ·  United Kingdom (4)  ·  South Korea (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Chile (2)  ·  Germany (2)  ·  Israel (2)

Top investigators

Jianmin Fang, Ph.D (6)  ·  Na Su, PhD (2)  ·  Wenjin Yin, M.D. (2)  ·  Dingwei Ye (1)  ·  Gu Yanhong (1)  ·  Haige Chen (1)  ·  Hailong Hu (1)  ·  Han Liang, Master (1)  ·  Han Liang, Ph.D (1)  ·  Hao Xu, Ph.D (1)  ·  Jieer Ying (1)  ·  Jieer Ying, MD (1)  ·  Jin Li, MD,PhD (1)

Results publications

PMID 33109737, PMID 40661136, PMID 40774226, PMID 41124210, PMID 41193372, PMID 41816563, PMID 42820775, PMID 42848391

NIH funding

2023 (2), 2025 (1)